KURA · Kura Oncology, Inc.

Track KURA — free

$11.71 -0.82 (-6.54%) At close · Aug 20

Market Cap

$1.11B

88.96M

Up next

Next earnings call

Nov 11, 2026 Est · unconfirmed · in 12 wks

FQ3-26 quarter ends

~Sep 30, 2026 Est

Latest filing: 10-Q

filed Aug 12, 2026

AI Brief

TL;DR.

Bullish

Bearish

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Ask ALVIS about this →

Equibles Rating

blended score · not investment advice

Overall

Buy

SellHoldBuy

Technical Strong Buy Momentum Very Strong Sentiment Bullish Fundamentals Fair Quant / Vol Very High

Market backdrop VIX 14.9 · calm Equity put/call 0.52

Technical

price trend

Strong Buy

50 / 200-day cross No cross

Price vs 200-day avg +21%

above

Price vs 50-day avg +13%

above

RSI (14) 62

neutral

MACD trend Positive

52-week position 85%

near high

Volume (OBV) Confirms

volume backs price

Momentum

relative strength

Very Strong

1-month return +12%

trailing

6-month return +34%

trailing

YTD return +13%

this year

Relative strength +23%

vs S&P · 6-mo

Sentiment

smart money

Bullish

Trend (MA cross) No cross

50d $10 › 200d $10 — 50d above 200d

Institutional flow Distributing

-1% holders QoQ · +29 funds added

Insider flow Accumulating

Net +$1.1M over 90 days · 0% sells

Short interest Falling

14.79% of float · ▼ -4.2% MoM · 11.8 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

220 holders — near 3-yr high, broad support

Squeeze score 82

high risk · 0–100

Fundamentals

Fair

Revenue growth +25%

Y/Y

EPS growth −57%

Y/Y

Free cash flow $-70.7M

Balance sheet $139.4M

net cash

Quant / Vol

risk profile

Very High

Volatility 60%

annualized · 1-yr

Max drawdown −39%

past year

ATR 5.6%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Strong Buy

0 · 3 · 4

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

+21% Bullish

Price vs 50-day avg

+13% Bullish

RSI (14)

62 Neutral

MACD trend

Positive Bullish

52-week position

85% Bullish

Volume (OBV)

Confirms Neutral

Market signals — smart money & positioning

Bullish · 3 of 6

Trend (MA cross) No cross

50d $10 › 200d $10 — 50d above 200d

Institutional flow Distributing

-1% holders QoQ · +29 funds added

Insider flow Accumulating

Net +$1.1M over 90 days · 0% sells

Short interest Falling

14.79% of float · ▼ -4.2% MoM · 11.8 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

220 holders — near 3-yr high, broad support

Price context

position in its 52-week range

Range low $7 Now $12 · 85% Range high $13

vs 200-day avg +21% vs 50-day avg +13%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings

Metric	Latest	Period	YoY
Net product revenue	$9.12M	FY2026 Q2	—

New patient starts	115	Q2 2026	—

Total prescriptions	250	Q2 2026	—

Payer coverage	93%	Q1 2026	—
Milestone payment from Kyowa Kirin	$135M	fourth quarter of 2025	—
Milestone payments from Kyowa Kirin	$30M	fourth quarter of 2025	—

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
KURA Kura Oncology, Inc. this stock	$1.11B	+12.7%	+25.2%	—	14.8%
ONC BeOne Medicines Ltd.	$557.05B	+21.5%	+22179.2%	856.5	0.1%
VRTX Vertex Pharmaceuticals Inc / Ma	$136.93B	+19.2%	+46.2%	31.5	1.6%
REGN Regeneron Pharmaceuticals, Inc.	$86.39B	+7.1%	+20.8%	20.8	3.3%
MRNA Moderna, Inc.	$69.62B	+352.1%	+4.3%	—	12.5%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

220

% held: 98.2%
Net QoQ: +2.5M sh
Top holder: BlackRock, Inc.

Held Float

View

Held by Funds

Fund positions

176

View

Short & Settlement

Short Interest Falling

Shares short

13.2M

Days to cover: 11.8d
Change: -571.6K sh

View

Short Volume

Short vol %

60%

As of: Aug 20, 2026

Short Total

View

Fails to Deliver

FTD shares

581

Value: $6.3K
As of: Jul 22, 2026

View

Off-Exchange

Off-exchange %

33.3%

Week of: Jul 13, 2026

Off-exch Lit

View

Smart Money

Insider Trades Net buying

Net (90d)

+$1.1M

Buyers / Sellers: 1 / 0

Buyers Sellers

View

Congressional Trades Buy

Member

Christopher L. Jacobs

Amount: $1.0K–$15.0K
Traded: Dec 12, 2022

View

Financials

Revenue (FY)

$67.5M

Net income (FY): $-278.7M
EPS diluted: $-3.18

View

Filings

SEC Filings

Latest

8-K

Filed: Aug 12, 2026
This year: 11

View

Proposed Sales

Value

$388.2K

Shares: 31.5K
Filed: Aug 19, 2026

View

Exempt Offerings

Offering

$150.0M

Filed: Feb 5, 2024

View

Earnings & Events

Earnings Calls

Last call

Aug 12, 2026

View

Performance

	5D	20D	120D	MTD	YTD
KURA	+16.1%	+12.1%	+34.1%	+30.0%	+12.7%
SPY	-2.0%	+3.3%	+11.2%	+2.1%	+11.8%
vs SPY	+18.0%	+8.8%	+23.0%	+27.9%	+0.9%

Key facts CIK 1422143 CUSIP 50127T109 13F (30d) 203 filings 199 filers Visit website Investor relations

KURA · Kura Oncology, Inc.

Price & Indicators

Up next

AI Brief

Equibles Rating

Technicals

Key metrics

Versus peers

At a glance

Performance